Moomoo AI 已提取核心信息
On January 9, 2024, Avenue Therapeutics, Inc. reported a significant corporate action through a Form 8-K filing with the SEC. The company's shareholders approved an increase in authorized common stock from 75 million to 200 million shares. This increase, known as the Authorized Share Increase, was formalized by an amendment to the company's Third Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State. Additionally, shareholders authorized the issuance of shares underlying warrants that could exceed 20% of the pre-issuance outstanding common stock, in compliance with Nasdaq Listing Rule 5635(d). These warrants were part of inducement letter agreements dated January 5, 2024. The consent for these actions was provided by holders of a majority of the voting power, representing approximately 56.4% of the capital stock as of the consent date. The company's Board of Directors also approved these measures. A Schedule 14C information statement will be distributed to shareholders, as required by SEC rules.
On January 9, 2024, Avenue Therapeutics, Inc. reported a significant corporate action through a Form 8-K filing with the SEC. The company's shareholders approved an increase in authorized common stock from 75 million to 200 million shares. This increase, known as the Authorized Share Increase, was formalized by an amendment to the company's Third Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State. Additionally, shareholders authorized the issuance of shares underlying warrants that could exceed 20% of the pre-issuance outstanding common stock, in compliance with Nasdaq Listing Rule 5635(d). These warrants were part of inducement letter agreements dated January 5, 2024. The consent for these actions was provided by holders of a majority of the voting power, representing approximately 56.4% of the capital stock as of the consent date. The company's Board of Directors also approved these measures. A Schedule 14C information statement will be distributed to shareholders, as required by SEC rules.
2024年1月9日，Avenue Therapeutics, Inc.通过向美国证券交易委员会提交的8-K表格报告了一项重大公司行动。该公司的股东批准将授权普通股从7500万股增加到2亿股。此次增持被称为授权增股，是通过对该公司向特拉华州国务卿提交的第三次修订和重述的公司注册证书的修正案正式确定的。此外，根据纳斯达克上市规则5635（d），股东授权发行可能超过发行前已发行普通股20％的股票标的认股权证。这些认股权证是2024年1月5日的激励信协议的一部分。这些行动的同意是由大多数投票权的持有人提供的，截至同意之日约占股本的56.4％。公司董事会也批准了这些措施。根据美国证券交易委员会规则的要求，附表14C的信息声明将分发给股东。
2024年1月9日，Avenue Therapeutics, Inc.通过向美国证券交易委员会提交的8-K表格报告了一项重大公司行动。该公司的股东批准将授权普通股从7500万股增加到2亿股。此次增持被称为授权增股，是通过对该公司向特拉华州国务卿提交的第三次修订和重述的公司注册证书的修正案正式确定的。此外，根据纳斯达克上市规则5635（d），股东授权发行可能超过发行前已发行普通股20％的股票标的认股权证。这些认股权证是2024年1月5日的激励信协议的一部分。这些行动的同意是由大多数投票权的持有人提供的，截至同意之日约占股本的56.4％。公司董事会也批准了这些措施。根据美国证券交易委员会规则的要求，附表14C的信息声明将分发给股东。
有用
没用